Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ANI Pharmaceuticals has acquired the US rights for Vancocin 125mg and 250mg capsules from Ireland-based biopharmaceutical company Shire.
Subscribe to our email newsletter
Additionally, ANI acquired approved ANDAs from Shire for the currently non-marketed products vancomycin hydrochloride injectable 500mg, 1gm and 10gm and vancomycin hydrochloride oral solution 250mg and 500mg.
In return, ANI paid $11m in cash for the rights to Vancocin together with existing inventories on hand.
After completion of the transition period, ANI intends to launch Vancocin capsules under its own label during the fourth quarter of 2014.
ANI president and CEO Arthur Przybyl said the company is happy to add Vancocin capsules to its portfolio of mature brand products.
"In addition, we will immediately begin exploring opportunities to launch both vancomycin injectable and vancomycin oral solution," Przybyl said.
"Year to date we have invested $23m in two mature brand acquisitions that will contribute a combined $9.4m in annual revenues and $8m in annual non-GAAP EBITDA.
"At the same time, we are continuing to advance our internal generic product development pipeline while selectively pursuing acquisitions and partnerships that augment those efforts."